Glioblastoma Multiforme (GBM) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Glioblastoma Multiforme (GBM) Therapeutics - Pipeline Assessment
and Market Forecasts to 2018
Published on September 2011

Report Summary

Glioblastoma Multiforme (GBM) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Glioblastoma Multiforme (GBM) Therapeutics - Pipeline
Assessment and Market Forecasts to 2018'. The report is an essential source of information and analysis on the global GBM market.
The report identifies the key trends shaping and driving the global GBM market. The report also provides insights on the prevalent
competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders.
Most importantly, the report provides valuable insights on the pipeline products within the global GBM sector. This report is built using
data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's
team of industry experts.

GlobalData estimates that the global GBM therapeutics market was valued at $370m in 2010, and is forecast to grow at a compound
annual growth rate (CAGR) of 2.4% to reach $449m by 2018. This low growth rate is primarily attributed to the patent expiry of
Temodal/Temodar (temozolomide, TMZ) in Europe in 2009 and in the US in 2014. The entry of low cost generics in Europe in 2010
has led to a decrease in the market valuation. TMZ has been an established standard of care for newly diagnosed GBM patients
since its approval in 2005 and has led to a considerable increase in the number of patients on chemotherapy. In addition, the late
stage pipeline products including Avastin (bevacizumab), enzastaurin and cilengitide for GBM are not expected to significantly drive
the market upon their launch as the clinical trial results have not shown a significant increase in survival rate.

Scope

The report provides information on the key drivers and challenges of the GBM market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) GBM market revenues data from 2005 to 2010,
forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends.
Pipeline candidates fall under major therapeutic classes such as angiogenic inhibitors, VEGF inhibitors, tyrosine kinase inhibitors,
gene therapy, anti-mitotic agents, stem cell therapy.
- Analysis of the current and future competition in the global GBM market. Key market players covered are Hoffmann-La Roche Ltd,
Merck, Eli Lilly, Ark Therapeutics and Antisense Pharma.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a
qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the GBM
therapeutics market.
- Analysis of key recent licensing and partnership agreements in GBM market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

Glioblastoma Multiforme (GBM) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 (From Slideshare) Page 1/8


- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by
identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global GBM market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to
impact the global GBM market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of
various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive
advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities
for consolidations, investments and strategic partnerships.
- What's the next big thing in the global GBM market landscape' ' Identify, understand and capitalize.

Table of Content

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Glioblastoma Multiforme (GBM) Therapeutics Introduction 7
2.1 Disease Overview 7
2.1.1 Classification of GBM 8
2.2 Epidemiology 9
2.3 Etiology and Pathophysiology 10
2.3.1 Environmental Factors 10
2.3.2 Genetic Factors 10
2.4 Symptoms 11
2.5 Prognosis 11
2.5.1 Tumor Size and Location 11
2.5.2 Treatment 11
2.5.3 Age 11
2.5.4 Karnofsky Performance Score (KPS) 11
2.6 Diagnosis 11
2.6.1 Neuroimaging Studies 11
2.6.2 Histology 12
2.7 Survival Rate 13
2.8 Treatment and Management Pattern 13
2.8.1 Surgery 14
2.8.2 Radiation Therapy (RT) 14
2.8.3 Chemotherapy 14
2.8.4 Targeted Therapy 14
2.9 GlobalData Pipeline Report Guidance 15
3 GBM Therapeutics: Market Characterization 16
3.1 GBM Therapeutics Market Size (2005-2010) ' Global 16
3.2 GBM Therapeutics Market Forecast (2010-2018) ' Global 17
3.3 GBM Therapeutics Market Size (2005-2010) ' The US 18



3.4 GBM Therapeutics Market Forecast (2010-2018) ' The US 19
3.5 GBM Therapeutics Market Size (2005-2010) ' The UK 20
3.6 GBM Therapeutics Market Forecast (2010-2018) ' The UK 21
3.7 GBM Therapeutics Market Size (2005-2010) ' France 22
3.8 GBM Therapeutics Market Forecast (2010-2018) ' France 23
3.9 GBM Therapeutics Market Size (2005-2010) ' Germany 24
3.10 GBM Therapeutics Market Forecast (2010-2018) ' Germany 25
3.11 GBM Therapeutics Market Size (2005-2010) ' Italy 26
3.12 GBM Therapeutics Market Forecast (2010-2018) ' Italy 27
3.13 GBM Therapeutics Market Size (2005-2010) ' Spain 28
3.14 GBM Therapeutics Market Forecast (2010-2018) ' Spain 29
3.15 GBM Therapeutics Market Size (2005-2010) ' Japan 30
3.16 GBM Therapeutics Market Forecast (2010-2018) ' Japan 31
3.17 Drivers and Barriers 32
3.17.1 Drivers for GBM Therapeutics Market 32
3.17.2 Barriers for GBM Therapeutics Market 32
3.18 Key Events Impacting the Future Market 33
3.19 Opportunity and Unmet Need 33
3.19.1 Unmet Need for Newly Diagnosed GBM Therapeutics 34
3.19.2 Unmet Need for Recurrent GBM Therapeutics 35
3.20 Key Takeaway 35
4 GBM Therapeutics Market ' Competitive Assessment 36
4.1 Overview 36
4.2 Strategic Competitor Assessment 36
4.3 Product Profile for the Major Marketed Products in GBM Therapeutics Market 37
4.3.1 Temodar (temozolomide, TMZ) 37
4.3.2 Gliadel (carmustine implant) 39
4.3.3 Avastin (bevacizumab) 41
4.4 Key Takeaway 43
5 GBM Therapeutics: Pipeline Assessment 44
5.1 Overview 44
5.2 Strategic Pipeline Assessment 44
5.3 Pipeline by Phases of Development 45
5.3.1 GBM Therapeutics-Phase III Pipeline 45
5.3.2 GBM Therapeutics - Phase II Pipeline 46
5.3.3 GBM Therapeutics-Phase I/II Pipeline 47
5.3.4 GBM Therapeutics - Phase I Pipeline 48
5.3.5 GBM Therapeutics - Pre-Clinical Pipeline 49
5.3.6 GBM Therapeutics - Discovery Pipeline 49
5.4 GBM Therapeutics - Pipeline by Mechanism of Action 50
5.5 Technology Trends Analytic Framework 52
5.6 Promising Drugs under Clinical Development 54
5.7 Profile for Promising Drugs 54
5.7.1 Cerepro (sitimagene ceradenovec) 54
5.7.2 Cilengitide (EMD 121974) 55
5.7.3 Enzastaurin (LY317615) 56
5.7.4 Immuncell-LC 57
5.7.5 Trabedersen 58



5.8 Key Takeaway 58
6 GBM Therapeutics: Clinical Trials Mapping 59
6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 59
6.2 Clinical Trials by Phase 60
6.3 Clinical Trials by Trial Status 61
6.4 Prominent Sponsors 62
6.5 Top Companies Participating in Therapeutics Clinical Trials 64
7 GBM Therapeutics: Strategic Assessment 65
7.1 Future Market Competition Scenario 65
8 GBM Therapeutics: Future Players 67
8.1 Introduction 67
8.2 Company Profiles 68
8.2.1 Hoffmann-La Roche Ltd 68
8.2.2 Merck & Co 71
8.2.3 Eli Lilly and Company 72
8.2.4 Ark Therapeutics Group 73
8.2.5 Antisense Pharma GmBH 74
8.2.6 Innocell Corporation 75
8.3 Other Companies in GBM Therapeutics Market 76
9 GBM Therapeutics: Licensing and Partnership Deals 79
10 Appendix 81
10.1 Market Definitions 81
10.2 Abbreviations 81
10.3 Methodology 82
10.3.1 Coverage 83
10.3.2 Secondary Research 83
10.3.3 Forecasting 83
10.3.4 Primary Research 86
10.3.5 Expert Panel Validation 86
10.4 Contact Us 86
10.5 Disclaimer 86
10.6 Bibliography 87

List of Tables

Table 1: Incidence and One Year Survival for GBM in Seven Major Markets, 2010 9
Table 2: GBM Survival Rates, 2004-2007 13
Table 3: GBM Therapeutics Market, Global, Revenue ($m), 2005-2010 16
Table 4: GBM Therapeutics Market, Global, Forecast ($m), 2010-2018 17
Table 5: GBM Therapeutics Market, The US, Revenue ($m), 2005-2010 18
Table 6: GBM Therapeutics Market, The US, Forecast ($m), 2010-2018 19
Table 7: GBM Therapeutics Market, The UK, Revenue ($m), 2005-2010 20
Table 8: GBM Therapeutics Market, The UK, Forecast ($m), 2010-2018 21
Table 9: GBM Therapeutics Market, France, Revenue ($m), 2005-2010 22
Table 10: GBM Therapeutics Market, France, Forecast ($m), 2010-2018 23
Table 11: GBM Therapeutics Market, Germany, Revenue ($m), 2005-2010 24
Table 12: GBM Therapeutics Market, Germany, Forecast ($m), 2010-2018 25
Table 13: GBM Therapeutics Market, Italy, Revenue ($m), 2005-2010 26



Table 14: GBM Therapeutics Market, Italy, Forecast ($m), 2010-2018 27
Table 15: GBM Therapeutics Market, Spain, Revenue ($m), 2005-2010 28
Table 16: GBM Therapeutics Market, Spain, Forecast ($m), 2010-2018 29
Table 17: GBM Therapeutics Market, Japan, Revenue ($m), 2005-2010 30
Table 18: GBM Therapeutics Market, Japan, Forecast ($m), 2010-2018 31
Table 19: Number (%) of Patients with Adverse Reactions, TMZ 38
Table 20: Common Adverse Events (AE), Gialdel 40
Table 21: AE for Avastin 43
Table 22: GBM Therapeutics, Phase III Pipeline, 2011 45
Table 23: GBM Therapeutics, Phase II Pipeline, 2011 46
Table 24: GBM Therapeutics, Phase I/II Pipeline, 2011 47
Table 25: GBM Therapeutics, Phase I Pipeline, 2011 48
Table 26: GBM Therapeutics, Preclinical Pipeline, 2011 49
Table 27: GBM Therapeutics, Preclinical Pipeline, 2011 49
Table 28: Mechanism of Action of Others in Figure 30 51
Table 29: GBM Therapeutics ' Most Promising Drugs Under Clinical Development, 2011 54
Table 30: CNS Adverse Events - Cerepro 55
Table 31: Enzastaurin Efficacy Response Results 56
Table 32: Enzastaurin Safety Results 57
Table 33: GBM Therapeutics -Clinical Trials by Region, 2011 59
Table 34: GBM Therapeutics, Global, Clinical Trials by Phase of Development, 2011 60
Table 35: GBM Therapeutics, Global, Clinical Trials by Trial Status, 2011 61
Table 36: GBM Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011 63
Table 37: GBM Therapeutics, Global, Clinical Trials by Top Companies, 2011 64
Table 38: F. Hoffmann-La Roche Ltd, Oncology Pipeline, 2010 69
Table 39: Roche ' GBM Pipeline Products, 2011 70
Table 40: Merck & Co. Inc, Oncology Pipeline, 2011 72
Table 41: Merck & Co. Inc , GBM Pipeline, 2011 72
Table 42: Eli Lilly, GBM Pipeline, 2011 73
Table 43: Ark Therapeutics 'Oncology Pipeline, 2011 74
Table 44: Ark Therapeutics 'GBM Pipeline, 2011 74
Table 45: Antisense Pharma 'Oncology Pipeline, 2011 75
Table 46: Antisense Pharma 'GBM Pipeline, 2011 75
Table 47: Innocell Corporation 'GBM Pipeline, 2011 75
Table 48: GBM Therapeutics Market ' Future Players, 2011 76
Table 49: GBM Therapeutics, Global, Deals, 2009'2011 79

List of Figures

Figure 1: GBM - WHO Grading Scheme for Astrocytoma 7
Figure 2: Classification of GBM 8
Figure 3: Morphologic Classification of GBM 9
Figure 4: MRI Scan of Brain with GBM 12
Figure 5: Histopathology Slide of GBM 13
Figure 6: GBM Therapeutics Market, Global, Revenue ($m), 2005-2010 16
Figure 7: GBM Therapeutics Market, Global, Forecast ($m), 2010-2018 17
Figure 8: GBM Therapeutics Market, The US, Revenue ($m), 2005-2010 18
Figure 9: GBM Therapeutics Market, The US, Forecast ($m), 2010-2018 19



Figure 10: GBM Therapeutics Market, The UK, Revenue ($m), 2005-2010 20
Figure 11: GBM Therapeutics Market, The UK, Forecast ($m), 2010-2018 21
Figure 12: GBM Therapeutics Market, France, Revenue ($m), 2005-2010 22
Figure 13: GBM Therapeutics Market, France, Forecast ($m), 2010-2018 23
Figure 14: GBM Therapeutics Market, Germany, Revenue ($m), 2005-2010 24
Figure 15: GBM Therapeutics Market, Germany, Forecast ($m), 2010-2018 25
Figure 16: GBM Therapeutics Market, Italy, Revenue ($m), 2005-2010 26
Figure 17: GBM Therapeutics Market, Italy, Forecast ($m), 2010-2018 27
Figure 18: GBM Therapeutics Market, Spain, Revenue ($m), 2005-2010 28
Figure 19: GBM Therapeutics Market, Spain, Forecast ($m), 2010-2018 29
Figure 20: GBM Therapeutics Market, Japan, Revenue ($m), 2005-2010 30
Figure 21: GBM Therapeutics Market, Japan, Forecast ($m), 2010-2018 31
Figure 22: GBM Therapeutics Market, Drivers and Restraints, 2011 33
Figure 23: Opportunity and Unmet Need in the Newly Diagnosed GBM Therapeutics Market, 2010 34
Figure 24: Opportunity and Unmet Need in the Recurrent GBM Therapeutics Market, 2010 35
Figure 25: Strategic Competitor Assessment of the Major Marketed Products in Newly Diagnosed GBM, 2010 36
Figure 26: Strategic Competitor Assessment of the Major Marketed Products in Recurrent GBM, 2010 37
Figure 27: GBM Therapeutics Pipeline by Phase of Development, 2011 45
Figure 28: GBM Therapeutics Pipeline by Mechanism of Action, 2011 50
Figure 29: Technology Trends Analytic Framework of the GBM Therapeutics Pipeline, 2011 52
Figure 30: Technology Trends Analytic Framework of the GBM Therapeutics Pipeline, Description, 2011 53
Figure 31: GBM Therapeutics - Clinical Trials by Region, 2011 59
Figure 32: GBM Therapeutics, Global, Clinical Trials by Phase of Development, 2011 60
Figure 33: GBM Therapeutics, Global, Clinical Trials by Trial Status, 2011 61
Figure 34: GBM Therapeutics, Global, Clinical Trials by Overall Sponsors, 2011 62
Figure 35: GBM Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011 63
Figure 36: GBM Therapeutics, Global, Clinical Trials by Top Companies, 2011 64
Figure 37: Implications for Future GBM Market Competition, 2011 66
Figure 38: GBM Therapeutics Market ' Pipeline by Company, 2011 67
Figure 39: GlobalData Market Forecasting Model 85

Companies Mentioned
Hoffmann-La Roche Ltd
Merck & Co
Eli Lilly and Company
Ark Therapeutics Group
Antisense Pharma GmBH
Innocell Corporation


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.

Glioblastoma Multiforme (GBM) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 3 500.00 Quantity: _____

Site License--USD 7 000.00 Quantity: _____

Corporate License--USD 10 500.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Glioblastoma Multiforme (GBM) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Recommandé

Recommandé

Contenu connexe

Plus de ReportLinker.com

Plus de ReportLinker.com (20)

Glioblastoma Multiforme (GBM) Therapeutics - Pipeline Assessment and Market Forecasts to 2018